These findings were in line with previous studies demonstrating increased IRG expression in active SLE [29,30], and were also supported by the observed reduced disease activity in SLE patients after inhibiting type I interferon (IFN) activity by blocking type I IFN-α/β/ω receptor (IFNAR) with anifrolumab [31], which is being evaluated in LN (ClinicalTrials.gov Identifier: NCT02547922). This evidence concerns the gene IFNAR1 and systemic lupus erythematosus.